Latest Insider Transactions at Acelrx Pharmaceuticals Inc (ACRX)
This section provides a real-time view of insider transactions for Acelrx Pharmaceuticals Inc (ACRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ACELRX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ACELRX PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
5,000
+2.35%
|
$0
$0.64 P/Share
|
|
Dec 02
2024
|
Raffi Asadorian Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
155
-0.41%
|
$0
$0.77 P/Share
|
|
Nov 27
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
5,000
+2.4%
|
$0
$0.73 P/Share
|
|
Aug 30
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
7,260
+3.54%
|
$7,260
$1.05 P/Share
|
|
Jun 24
2024
|
Marina Bozilenko |
BUY
Grant, award, or other acquisition
|
Direct |
2,174
+31.26%
|
-
|
|
Jun 24
2024
|
Abhinav Jain |
BUY
Grant, award, or other acquisition
|
Direct |
2,174
+41.66%
|
-
|
|
Jun 24
2024
|
Jill Marie Broadfoot |
BUY
Grant, award, or other acquisition
|
Direct |
2,174
+33.68%
|
-
|
|
Jun 24
2024
|
Adrian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
2,174
+14.01%
|
-
|
|
Jun 24
2024
|
Stephen J Hoffman |
BUY
Grant, award, or other acquisition
|
Direct |
2,174
+32.13%
|
-
|
|
Jun 24
2024
|
Mark A Wan |
BUY
Grant, award, or other acquisition
|
Direct |
2,174
+32.13%
|
-
|
|
Jun 14
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
1,304
+0.72%
|
$1,304
$1.08 P/Share
|
|
Jun 13
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
4,570
+2.48%
|
$0
$0.97 P/Share
|
|
Jun 12
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
4,126
+2.3%
|
$0
$0.97 P/Share
|
|
Mar 15
2024
|
Nantahala Capital Management, LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
755,000
+27.48%
|
$3,775,000
$5.0 P/Share
|
|
Mar 12
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+4.47%
|
$8,000
$1.12 P/Share
|
|
Mar 11
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.61%
|
$1,000
$1.12 P/Share
|
|
Mar 03
2024
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
450
-0.76%
|
$450
$1.3 P/Share
|
|
Mar 03
2024
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
406
-1.28%
|
$406
$1.3 P/Share
|
|
Mar 03
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,623
-0.99%
|
$1,623
$1.3 P/Share
|
|
Mar 03
2024
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-1.46%
|
$558
$1.3 P/Share
|
|
Feb 14
2024
|
Pamela P Palmer Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+25.23%
|
-
|
|
Feb 14
2024
|
Raffi Asadorian Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+31.98%
|
-
|
|
Feb 14
2024
|
Badri N Dasu Chief Engineering Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,667
+31.55%
|
-
|
|
Feb 14
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
58,667
+27.66%
|
-
|
|
Feb 11
2024
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-2.22%
|
$801
$1.1 P/Share
|
|
Feb 11
2024
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
809
-4.5%
|
$809
$1.1 P/Share
|
|
Feb 11
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,723
-3.78%
|
$3,723
$1.1 P/Share
|
|
Feb 11
2024
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
895
-4.22%
|
$895
$1.1 P/Share
|
|
Feb 10
2024
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-2.17%
|
$801
$1.1 P/Share
|
|
Feb 10
2024
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
809
-4.31%
|
$809
$1.1 P/Share
|
|
Feb 10
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,320
-3.26%
|
$3,320
$1.1 P/Share
|
|
Feb 10
2024
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
895
-4.05%
|
$895
$1.1 P/Share
|
|
Jan 22
2024
|
Abhinav Jain |
BUY
Grant, award, or other acquisition
|
Direct |
871
+50.0%
|
-
|
|
Dec 13
2023
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
10,000
+8.94%
|
$0
$0.73 P/Share
|
|
Oct 10
2023
|
Richard Afable Director |
BUY
Grant, award, or other acquisition
|
Direct |
581
+19.06%
|
-
|
|
Oct 10
2023
|
Stephen J Hoffman |
BUY
Grant, award, or other acquisition
|
Direct |
581
+19.37%
|
-
|
|
Oct 10
2023
|
Mark A Wan |
BUY
Grant, award, or other acquisition
|
Direct |
581
+19.37%
|
-
|
|
Oct 10
2023
|
Marina Bozilenko |
BUY
Grant, award, or other acquisition
|
Direct |
581
+18.23%
|
-
|
|
Oct 10
2023
|
Adrian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
581
+4.95%
|
-
|
|
Oct 10
2023
|
Howard B Rosen Director |
BUY
Grant, award, or other acquisition
|
Direct |
581
+9.89%
|
-
|
|
Oct 10
2023
|
Jill Marie Broadfoot |
BUY
Grant, award, or other acquisition
|
Direct |
581
+21.62%
|
-
|
|
Sep 11
2023
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
10,000
+9.82%
|
$0
$0.8 P/Share
|
|
Aug 25
2023
|
Pamela P Palmer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,442
-19.48%
|
$7,442
$1.09 P/Share
|
|
Aug 24
2023
|
Pamela P Palmer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,514
-19.94%
|
$9,514
$1.17 P/Share
|
|
Mar 03
2023
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
398
-2.08%
|
$398
$1.31 P/Share
|
|
Mar 03
2023
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,703
-2.6%
|
$1,703
$1.31 P/Share
|
|
Mar 03
2023
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
510
-2.26%
|
$510
$1.31 P/Share
|
|
Mar 03
2023
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
570
-1.3%
|
$570
$1.31 P/Share
|
|
Feb 11
2023
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
873
-3.72%
|
$873
$1.68 P/Share
|
|
Feb 11
2023
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
776
-3.89%
|
$776
$1.68 P/Share
|